|
Variables
|
csDMARDs (n=43)
|
TNFi (n=64)
|
P-value
|
|---|
|
Cardiovascular disease risk factors
|
|
Age, median years (IQR)
|
58.6 (53.0, 66.0)
|
58.1 (49.3, 67.0)
|
0.839
|
|
Female sex
|
33 (76.7)
|
54 (84.4)
|
0.321
|
|
Obesity
|
5 (11.6)
|
7 (10.9)
|
0.999
|
|
Hypertension
|
19 (44.2)
|
30 (46.9)
|
0.784
|
|
Anti-hypertensive drug
|
17 (39.5)
|
28 (43.8)
|
0.784
|
|
Smoking status, ever
|
18 (42.9)
|
30 (46.9)
|
0.684
|
|
Dyslipidaemia
|
30 (40.2)
|
34 (59.8)
|
0.085
|
|
Current statin use
|
13 (34.2)
|
10 (15.9)
|
0.033
|
|
Diabetes mellitus
|
3 (7.0)
|
3 (4.7)
|
0.676
|
|
Anti-diabetic medication
|
1 (2.3)
|
1 (1.5)
|
0.999
|
|
CVD risk factors, median (IQR)
|
2 (1, 3)
|
2 (1, 3)
|
0.199
|
|
Rheumatoid arthritis characteristics and treatment
|
|
RF and/or ACPA positive
|
28 (65.1)
|
33 (51.6)
|
0.165
|
|
Disease duration, median years (IQR)
|
14.1 (11.5)
|
15.4 (10.5)
|
0.538
|
|
Methotrexate
|
38 (88.4)
|
52 (81.3)
|
0.192
|
|
Leflunomide
|
5 (17.9)
|
12 (19.0)
|
0.999
|
|
Hydroxychloroquine
|
9 (31.0)
|
5 (7.8)
|
0.009
|
|
Prednisone > 5 mg daily
|
7 (7.7)
|
5 (5.5)
|
0.823
|
|
NSAIDs
|
6 (20.7)
|
22 (34.4)
|
0.227
|
- ACPA, anti-citrullinated peptides antibodies; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitors. All data reported as absolute numbers (percentage) otherwise specified. P-value refers to the chi-squared or Fisher test for categorical variables or independent samples T-test for continuous variables
